Bcr-Abl
Los inhibidores de Bcr-Abl son terapias dirigidas que inhiben la proteína de fusión Bcr-Abl, formada debido a la translocación del cromosoma Filadelfia y que es un impulsor de la leucemia mieloide crónica (LMC). Esta proteína también influye en la angiogénesis, contribuyendo a la progresión tumoral. Los inhibidores de Bcr-Abl son cruciales en el tratamiento de la LMC y se están explorando por su potencial para inhibir la angiogénesis en varios tipos de cáncer. En CymitQuimica, ofrecemos inhibidores de Bcr-Abl de alta calidad para apoyar su investigación en biología del cáncer, angiogénesis y terapias dirigidas.
Se han encontrado 102 productos de "Bcr-Abl"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
cSRC/BCR-ABL1-IN-1
<p>cSRC/BCR-ABL1-IN-1 (compound 16a) is a dual-target inhibitor of the cSRC/BCR-ABL1 kinases.</p>Fórmula:C24H27ClN6O4Forma y color:SolidPeso molecular:498.96Asciminib hydrochloride
CAS:<p>Asciminib (ABL001) hydrochloride is a selective and potent mutant BCR-ABL1 inhibitor that inhibits Ba/F3 cell growth (IC50: 0.25 nM).</p>Fórmula:C20H19Cl2F2N5O3Forma y color:SolidPeso molecular:486.3Vodobatinib
CAS:<p>Vodobatinib (K-0706) is a novel 3rd generation (3G) TKI effective against wild-type and mutated BCR-ABL1 with limited off-target activity.</p>Fórmula:C27H20ClN3O2Pureza:99.06% - 99.55%Forma y color:SolidPeso molecular:453.92GNF-7
CAS:<p>GNF-7 is Bcr-Abl WT and Bcr-Abl T315I inhibitor with IC50 of 133 nM and 61 nM, respectively.</p>Fórmula:C28H24F3N7O2Pureza:97.05% - 99.7%Forma y color:SolidPeso molecular:547.53Degrasyn
CAS:<p>Degrasyn (WP1130) inhibits DUBs (USP5, UCH-L1, USP9x, USP14, UCH37) and Bcr/Abl without affecting the 20S proteasome.</p>Fórmula:C19H18BrN3OPureza:98.32% - 99.98%Forma y color:SolidPeso molecular:384.27Nocodazole
CAS:<p>Nocodazole: synthetic microtubule polymerization blocker, also impedes Abl with low IC50; binds to beta-tubulin.</p>Fórmula:C14H11N3O3SPureza:98% - 99.91%Forma y color:Physical Description White Powder (Ntp 1992)Peso molecular:301.32Rebastinib
CAS:<p>DCC-2036 (Rebastinib (DCC-2036)) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC,</p>Fórmula:C30H28FN7O3Pureza:99.53% - 99.79%Forma y color:SolidPeso molecular:553.59Ponatinib
CAS:<p>Ponatinib (AP24534) is an orally available, multitargeted kinase inhibitor (IC50s: 0.37/1.1/1.5/2.2/5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively</p>Fórmula:C29H27F3N6OPureza:98% - 99.60%Forma y color:SolidPeso molecular:532.56NVP-BAW2881
CAS:<p>NVP-BAW2881 (BAW2881) is a potent and selective VEGFR inhibitor with activity to inhibit chronic and acute skin inflammation.</p>Fórmula:C22H15F3N4O2Pureza:98.19% - 99.97%Forma y color:SolidPeso molecular:424.38AT9283
CAS:<p>AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).</p>Fórmula:C19H23N7O2Pureza:99.83% - 99.98%Forma y color:SolidPeso molecular:381.43Multi-kinase inhibitor 1
CAS:<p>Multi-kinase inhibitor 1 (Multi-kinase inhibitor I) is a Multi-kinase inhibitor.</p>Fórmula:C20H17F3N4O3Pureza:99.34%Forma y color:SolidPeso molecular:418.37Flumatinib
CAS:<p>Flumatinib (HHGV678) is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.</p>Fórmula:C29H29F3N8OPureza:99.39% - 99.95%Forma y color:SolidPeso molecular:562.59AG1024
CAS:<p>AG1024 (Tyrphostin) suppresses IGF-1R autophosphorylation(IC50=7 μM), and is less potent for IR(IC50=57 μM).</p>Fórmula:C14H13BrN2OPureza:98% - 99.37%Forma y color:SolidPeso molecular:305.17Olverembatinib dimesylate
CAS:<p>Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I).</p>Fórmula:C29H27F3N6O·2CH4O3SPureza:97.66% - >99.99%Forma y color:SolidPeso molecular:724.77Dasatinib N-oxide
CAS:<p>Dasatinib N-oxide is a key metabolite and potential impurity of the kinase inhibitor dasatinib.</p>Fórmula:C22H26ClN7O3SPureza:98.54% - 99.94%Forma y color:SolidPeso molecular:504Olverembatinib
CAS:<p>Olverembatinib (GZD 824) is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT, IC50: 0.34 nM) and Bcr-Abl(T315I, IC50: 0.68 nM).</p>Fórmula:C29H27F3N6OPureza:98.53% - >99.99%Forma y color:SolidPeso molecular:532.56GNF-2
CAS:<p>GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl.</p>Fórmula:C18H13F3N4O2Pureza:98.17% - ≥95%Forma y color:SolidPeso molecular:374.32GMB-475
CAS:<p>GMB-475, a PROTAC-based BCR-ABL1 inhibitor, tackles drug resistance by promoting VHL-mediated degradation.</p>Fórmula:C43H46F3N7O7SPureza:98.78% - >99.99%Forma y color:SolidPeso molecular:861.93KW-2449
CAS:<p>KW-2449 is a multiple-targeted inhibitor, mostly for Flt3, modestly effective to Bcr-Abl, FGFR1, and Aurora A; little inhibitory on PDGFRβ, IGF-1R, EGFR.</p>Fórmula:C20H20N4OPureza:98.43% - 99.69%Forma y color:SolidPeso molecular:332.4BGG463
CAS:<p>BGG463 (K 0859) can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with an IC50 of 0.25 μM, 0.09 μM and 0.590 μM, respectively.</p>Fórmula:C30H29F3N6O3Pureza:95.05% - >99.99%Forma y color:SolidPeso molecular:578.58
